Tricida to Present at the 40th Annual J.P. Morgan Healthcare Conference
15 Dezembro 2021 - 3:58PM
Tricida, Inc. (Nasdaq: TCDA) today announced that it will
present at the 40th Annual J.P. Morgan Healthcare Conference on
Thursday, January 13, 2022 at 10:30 am PT / 1:30 pm ET. Gerrit
Klaerner, Ph.D., Tricida’s Founder, President and CEO, will provide
a company overview, business update and progress on the company’s
key initiatives.
A live webcast of the presentation will be accessible on the
Tricida website at IR.Tricida.com. An archive of the webcast will
be available for 30 days following the presentation.
About Tricida
Tricida, Inc. is a pharmaceutical company focused on the
development and commercialization of its investigational drug
candidate, veverimer, a non-absorbed, orally-administered polymer
designed to slow chronic kidney disease (CKD) progression in
patients with metabolic acidosis and CKD. Tricida is currently
conducting a renal outcomes clinical trial, VALOR-CKD, to determine
if veverimer slows CKD progression in patients with metabolic
acidosis associated with CKD. Metabolic acidosis is a condition
commonly caused by CKD that is believed to accelerate the
progression of kidney deterioration. There are currently no
therapies approved by the FDA to slow progression of kidney disease
by correcting chronic metabolic acidosis in patients with CKD. It
is estimated to pose a health risk to approximately three million
patients with CKD in the United States.
For more information about Tricida, please
visit www.Tricida.com.
Contact: Jackie Cossmon, IRCTricida, Inc.Senior Vice President
of Investor Relations and CommunicationsIR@Tricida.com
Tricida (NASDAQ:TCDA)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Tricida (NASDAQ:TCDA)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
Notícias em tempo-real sobre Tricida Inc da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de